Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dow Jones Industrial Average ETF (DIA) vs Pfizer Inc (PFE) Price & Performance

Dow Jones Industrial Average ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Dow Jones Industrial Average ETF vs Pfizer Inc — how do they compare? Dow Jones Industrial Average ETF trades at $524.55, while Pfizer Inc trades at $24.26 (market cap $138.21B). The key difference: Pfizer Inc pays a 7.09% dividend while Dow Jones Industrial Average ETF pays none, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.

DIAPFE
52-Week High
$530.02$28.56
52-Week Low
$435.72$23.29
Market Cap
$138.21B
Volume
29,869,932
Sector
Health
Enterprise Value
$188.87B
Dividend Yield
7.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dow Jones Industrial Average ETF

DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $524.40, down 0.27% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the Dow Jones Industrial Average's 30 blue-chip stocks, providing diversified exposure to large-cap U.S. equities. Recent news highlights its 52-week high achievement and inclusion of Alphabet, boosting its tech weighting. Dividend distributions continue with scheduled payouts through mid-2026.

Outlook remains positive given the Dow's 8% year-to-date gain and DIA's 10-year average annual return of 13.3%. Key opportunities include broad market exposure and dividend income, while risks involve Fed policy shifts and concentration in cyclical sectors. Analyst sentiment is favorable due to the ETF's low-cost structure and historical performance.

Pfizer Inc

Pfizer (PFE) trades at $24.25, up 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.75, beating expectations, and maintains a dividend of $0.43 per share. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, with key catalysts expected in 2026. Financials show revenue of $62.58B in 2025, with a net income margin of 11.83% and a P/E ratio of 18.69.

The outlook for Pfizer is mixed, with analyst consensus leaning toward Hold (58.98%) but a price target of $28.78 suggesting potential upside. Investment opportunities include a strong dividend yield and pipeline advancements, while risks involve patent cliffs and competitive pressures. The stock's current valuation appears reasonable, but execution on pipeline developments is critical for future growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dow Jones Industrial Average ETF

The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on DIA

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE